A disintegrin and metalloproteinase 22 activates integrin β 1 through its disintegrin domain to promote the progression of pituitary adenoma
Neuro-Oncology · 2024
DOI: 10.1093/neuonc/noad148 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2024. Verfasst von Biao Xing und 17 weiteren Autor:innen. Beteiligte Einrichtung: Sino-German Neuro-Oncology Molecular Laboratory, Department of Neurosurgery, Tongji Hospital of Tongji medical college of Huazhong University of Scie…. Hauptthemen laut MEDLINE: Disintegrins, Pituitary Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Approximately 35% of pituitary adenoma (PA) display an aggressive profile, resulting in low surgical total resection rates, high recurrence rates, and worse prognosis. However, the molecular mechanism of PA invasion remains poorly understood. Although “a disintegrin and metalloproteinases” (ADAMs) are associated with the progression of many tumors, there are no reports on ADAM22 in PA.
Methods
PA transcriptomics databases and clinical specimens were used to analyze the expression of ADAM22. PA cell lines overexpressing wild-type ADAM22, the point mutation ADAM22, the mutated ADAM22 without disintegrin domain, and knocking down ADAM22 were generated. Cell proliferation/invasion assays, flow cytometry, immunohistochemistry, immunofluorescence, co-immunoprecipitation, mass spectrometry, Reverse transcription-quantitative real-time PCR, phos-tag SDS-PAGE, and Western blot were performed for function and mechanism research. Nude mice xenograft models and rat prolactinoma orthotopic models were used to validate in vitro findings.
Results
ADAM22 was significantly overexpressed in PA and could promote the proliferation, migration, and invasion of PA cells. ADAM22 interacted with integrin β1 (ITGB1) and activated FAK/PI3K and FAK/ERK signaling pathways through its disintegrin domain to promote PA progression. ADAM22 was phosphorylated by PKA and recruited 14-3-3, thereby delaying its degradation. ITGB1-targeted inhibitor (anti-itgb1) exerted antitumor effects and synergistic effects in combination with somatostatin analogs or dopamine agonists in treating PA.
Conclusions
ADAM22 was upregulated in PA and was able to promote PA proliferation, migration, and invasion by activating ITGB1 signaling. PKA may regulate the degradation of ADAM22 through post-transcriptional modification levels. ITGB1 may be a potential therapeutic target for PA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sino-German Neuro-Oncology Molecular Laboratory, Department of Neurosurgery, Tongji Hospital of Tongji medical college of Huazhong University of Science and Technology, Wuhan, China.
- Department of Orthopedics, Tongji Hospital of Tongji medical college of Huazhong University of Science and Technology, Wuhan, China.
- Department of Neurosurgery, Philipps-University Marburg, University Hospital Marburg (UKGM), Marburg, Germany.
- Center for Mind, Brain and Behavior (CMBB), Marburg, Germany.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Xing, B., Lei, Z., Wang, Z., Wang, Q., Jiang, Q., Zhang, Z., Liu, X., Qi, Y., Li, S., Guo, X., Liu, Y., Li, X., Shu, K., Zhang, H., Bartsch, J. W., Nimsky, C., Huang, Y., & Lei, T. (2024). A disintegrin and metalloproteinase 22 activates integrin β 1 through its disintegrin domain to promote the progression of pituitary adenoma. Neuro-Oncology. https://doi.org/10.1093/neuonc/noad148
Vancouver
Xing B, Lei Z, Wang Z, Wang Q, Jiang Q, Zhang Z, et al. A disintegrin and metalloproteinase 22 activates integrin β 1 through its disintegrin domain to promote the progression of pituitary adenoma. Neuro-Oncology. 2024. doi:10.1093/neuonc/noad148
BibTeX
@article{Xing2024,
author = {Xing, Biao and Lei, Zhuowei and Wang, Zihan and Wang, Quanji and Jiang, Qian and Zhang, Zhuo and Liu, Xiaojin and Qi, Yiwei and Li, Sihan and Guo, Xiang and Liu, Yanchao and Li, Xingbo and Shu, Kai and Zhang, Huaqiu and Bartsch, Jörg Walter and Nimsky, Christopher and Huang, Yimin and Lei, Ting},
title = {A disintegrin and metalloproteinase 22 activates integrin β 1 through its disintegrin domain to promote the progression of pituitary adenoma},
journal = {Neuro-Oncology},
year = {2024},
doi = {10.1093/neuonc/noad148}
}
EUVIMED